ArticleCancer cell2024
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.
Abstract read
In one paragraph
Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Current progress and emerging trends of car-based immunotherapy for hepatocellular carcinoma: a data-driven atlas from multidatabase integration.Frontiers in immunology · 2026Pooled it
- Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.Cell reports. Medicine · 2026Trial
- Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial.Nature medicine · 2025Trial
- Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial.Signal transduction and targeted therapy · 2024Trial
- CXCL13-expressing CD4Oncoimmunology · 2026Article
- Antibody-lectin chimeras for glyco-immune checkpoint blockade.Nature biotechnology · 2026Article
- Spatial T lymphocyte infiltration into the primary melanoma tumor associates with survival.Melanoma research · 2026Article
- Nanoparticle-mediated dual delivery of MHC class I and II antigens enhances T cell immunity and anti-tumor potency.Biomaterials · 2026Article
- Integrated Immunological Analysis of Interactions Between CXCL13+ T Cells and LAMP3+ DC in the Immunotherapy Response of Bladder Cancer.Molecular carcinogenesis · 2026Article
- Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer.Journal for immunotherapy of cancer · 2026Article
- Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer.Science (New York, N.Y.) · 2026Article
- Genotype-driven tumor ecosystems drive immune evasion and immunotherapy resistance in melanoma.Molecular cancer · 2026Article
- FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The spatial architecture of tumor immunity: Emerging predictive biomarkers across cancer.Immunologic research · 2026Review
- PRMT7 restricts CD8+ T cells expansion via the NF-ΚB pathway.Nature communications · 2026Article
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.Blood neoplasia · 2026Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Update of
Authors and funding
12 authors.
Gabriel Espinosa-CarrascoImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: gespinosa@idibell.cat.
Edison ChiuImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aurora ScrivoDepartment of Developmental and Molecular Biology, and Institute for Aging Studies, Albert Einstein College of Medicine, Bronx, NY, USA.
Paul ZumboDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA; Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.
Asim DaveImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Doron BetelApplied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Sung Wook KangSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
Hee-Jin JangSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
Matthew D HellmannOncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Bryan M BurtSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA; Division of Thoracic Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Hyun-Sung LeeSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
Andrea SchietingerImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA. Electronic address: schietia@mskcc.org.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MProteomic determinants of response to checkpoint blockade in malignant pleuralmesotheliomaR37CA248478 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Bryan Michael Burt · 2021 to 2026
$2.9MSpatiotemporal regulation of T cell fate decisions in cancerDP2CA225212 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHIETINGER, ANDREA · 2017 to 2017
$2.6MTOX-driven CD8 T cell differentiation and dysfunction in tumorsR01CA269733 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Schietinger · 2023 to 2026
$2.4MNOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPYR21AI159379 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI LEE, HYUN-SUNG, REDONDO, MARIA JOSE · 2023 to 2024
$440kBD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430kUncovering the role of individual RNA helicases in cancer through specific chemical inhibitionF30CA203522 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARKOVICH, KRISTER · 2016 to 2018
$121kNCI NIH HHS DP2 CA225212NCI NIH HHS F30 CA203522NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA269733NCI NIH HHS R37 CA248478NCRR NIH HHS S10 RR024574NIAID NIH HHS R21 AI159379
Abstract
Tumor-specific CD8
Indexed as
CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesAnimalsCell Line, TumorDendritic CellsHumansImmune Checkpoint InhibitorsImmunotherapyImmunotherapy, AdoptiveMiceMice, Inbred C57BLNeoplasmsTumor MicroenvironmentImmune Checkpoint Inhibitorsadoptive T cell transferCancercancer immunotherapyCD4 T cellCD8 T celldendritic cellimmune checkpoint blockadetriadtumortumor antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.